Phase II study of 21 day schedule oral etoposide in children
- 31 October 1997
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 33 (11) , 1816-1822
- https://doi.org/10.1016/s0959-8049(97)00201-3
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide.Journal of Clinical Oncology, 1995
- Phase I study of oral etoposide in children with refractory solid tumors.Journal of Clinical Oncology, 1994
- 21-day schedule oral etoposide in children— a feasibility studyEuropean Journal Of Cancer, 1993
- Prolonged oral etoposide in small cell lung cancerAnnals of Oncology, 1993
- Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer.Journal of Clinical Oncology, 1993
- Bioavailability of low-dose oral etoposide.Journal of Clinical Oncology, 1993
- Chronic Administration of Etoposide in the Treatment of Non-Hodgkin's LymphomaLeukemia & Lymphoma, 1993
- International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.Journal of Clinical Oncology, 1988
- In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapyCancer Chemotherapy and Pharmacology, 1987
- Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assayCancer Chemotherapy and Pharmacology, 1985